NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT01743131 2025-12-11Abatacept as GVHD Prophylaxis Phase 2Boston Children's HospitalPhase 2 Completed186 enrolled 14 charts 1 FDA
NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 1 FDA